title: FK 506 as primary immunosuppressive therapy in renal transplantation.
authors.affiliation: Renal Unit, St Mary's Hospital, Paddington, London, England.
authors.forename: R
authors.initials: R
authors.lastname: Preston
authors.forename: S
authors.initials: S
authors.lastname: Ball
authors.forename: T
authors.initials: T
authors.lastname: Cairns
authors.forename: J
authors.initials: J
authors.lastname: Contis
authors.forename: N
authors.initials: N
authors.lastname: Hakim
authors.forename: A
authors.initials: A
authors.lastname: Palmer
authors.forename: V
authors.initials: V
authors.lastname: Papalois
authors.forename: D
authors.initials: D
authors.lastname: Taube
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D003404:Creatinine; D016559:Tacrolimus